A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease
JCO Precision Oncology · 2024
DOI: 10.1200/po.24.00269 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Brandon A Mahal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL. Hauptthemen laut MEDLINE: Early Detection of Cancer, Neoplasm Grading, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Indolent prostate cancer (PCa) is prevalent in the intended use population (adults age 50-79 years) for blood-based multicancer early detection (MCED) tests. We examined the detectability of PCa by a clinically validated, targeted methylation–based MCED test. METHODS Detectability by Gleason grade group (GG), clinical stage, association of detection status with tumor methylated fraction (TMeF), and overall survival (OS) were assessed in substudy 3 of Circulating Cell-Free Genome Atlas (CCGA; ClinicalTrials.gov identifier: NCT02889978 ) and PATHFINDER (ClinicalTrials.gov identifier: NCT04241796 ) studies. RESULTS Test sensitivity for PCa in substudy 3 of CCGA was 11.2% (47/420). The test detected 0 (0%) of 58 low-grade (GG1), 3 (1.9%) of 157 favorable intermediate-grade (GG2), 4 (5.1%) of 78 unfavorable intermediate-grade (GG3), and 36 (31.9%) of 113 high-grade (GG4 and 5) cancers and 3 (3.2%) of 95 stage I, 11 (4.7%) of 235 stage II, 7 (14.9%) of 47 stage III, and 22 (81.5%) of 27 stage IV cases. The median TMeF was higher for detected than nondetected cases (2,106.0 parts per million [PPM]; IQR, 349.8-24,376.3 v 24.4 PPM; IQR, 17.8-38.5; P < .05). Nondetected cases had better OS ( P < .05; hazard ratio [HR], 0.263 [95% CI, 0.104 to 0.533]) and detected cases had similar survival ( P = .2; HR, 0.672 [95% CI, 0.323 to 1.21]) compared with SEER adjusted for age, GG, and stage. Performance was similar in PATHFINDER, with no detected GG1/2 (0/13) or stage I/II (0/16) cases. CONCLUSION This MCED test preferentially detects high-grade, clinically significant PCa. Use in population-based screening programs in addition to standard-of-care screening is unlikely to exacerbate overdiagnosis of indolent PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.
- GRAIL, Inc, Menlo Park, CA.
- Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
ORCID-Profile: Brandon A Mahal, Matthew Margolis, Earl Hubbell, Cheng Chen, John Abran, Jordan J Kartlitz, Alexander W Wyatt, Eric A Klein
Zitieren
APA
Mahal, B. A., Margolis, M., Hubbell, E., Chen, C., Venstrom, J. M., Abran, J., Kartlitz, J. J., Wyatt, A. W., & Klein, E. A. (2024). A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease. JCO Precision Oncology. https://doi.org/10.1200/po.24.00269
Vancouver
Mahal BA, Margolis M, Hubbell E, Chen C, Venstrom JM, Abran J, et al. A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease. JCO Precision Oncology. 2024. doi:10.1200/po.24.00269
BibTeX
@article{Mahal2024,
author = {Mahal, Brandon A and Margolis, Matthew and Hubbell, Earl and Chen, Cheng and Venstrom, Jeffrey M and Abran, John and Kartlitz, Jordan J and Wyatt, Alexander W and Klein, Eric A},
title = {A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.24.00269}
}
EUVIMED